You are here
Index
The index relates to the hard copy.
A
accountability and management, 80–97
see also finance; patient blood management
acronyms and abbreviations list, 182–184
administered finances, 105–106
special account, 100, 101
administrative tribunal decisions, 89
advertising and market research, 169
age demographic of staff, 93
agency resource statements, 173–174
alpha1-proteinase inhibitor deficiency, 55
anaemia, 68
annual performance reporting statement, 20–77
annual reports, 56
errata, 172
list of requirements, 175–181
Anti-D, 65
apheresis plasma, 35, 36, 71
donors, 6, 42, 43, 44
assets and asset management, 103, 107
administered items, 106
Audit Committee, 21, 83, 84–85, 87, 161
Australian Bleeding Disorders Registry (ABDR),
7, 56, 60
Australian Capital Territory, 56
Canberra plasma donor centre, 42, 44
Australian Commission on Safety and Quality in Health Care (ACSQHC), 69, 73
Australian Defence Force, 43
Australian Haemovigilance Minimum Data Set, 56, 71
Australian Information Commissioner, 89
Australian National Audit Office (Auditor-General), 83, 89
Australian Public Service Commission Employee Census, 90–91
Australian Red Cross Blood Service (Blood Service),
15, 41–44
data security breach, 44
National Managed Fund (Blood and Blood Products) Special Account, 101
Output Based Funding Model (OBFM), 8, 28, 41
Perth Processing Centre, 63
see also fresh blood
B
balance sheet, 103
Bio-Rad Laboratories Pty Ltd, 32, 48
Bioverativ Australia Pty Ltd, 32, 47–48, 49, 165
bleeding disorders (haemophilia), 7, 15, 56, 60, 62
clotting factors, 49, 55
see also Factor VIIa; Factor VIII; Factor IX
blood cells, see red blood cells
blood donations, 6, 42, 43, 44
Blood Sector Data and Systems roadmap, 58
Blood Service, see Australian Red Cross Blood Service
BloodNet, 6, 25, 58, 59, 60–61
Fate Module, 6, 55
BloodNet User Reference Group, 59
BloodSafe eLearning Australia, 13, 68, 72
BloodSTAR, 51, 52, 53, 56, 59
Board, 14–17, 87, 156–161
budget, see finance
Business Committee, 82, 87
Business Contingency Plan, 57
Business Plan, 87
C
C1 Esterase, 36, 166
Canberra plasma donor centre, 42, 44
capability reviews, 89
Chief Executive (General Manager), 3, 57, 82, 83, 84
review of year, 8–12
chronic obstructive pulmonary disease, 55
classification of staff, 92–93, 94
clinical demand, see demand
clotting factors, 49, 55
see also Factor VIIa; Factor VIII; Factor IX
Comcare, reportable incidents lodged with, 97
Commonwealth Ombudsman, 89
communication and promotion, 70–71
see also information communication technology
competitive tendering and contracting, 108
conferences and events, 9, 70–71
consultants, 109
contingency plans, 57
contracts, see purchasing
Corporate Plan, 21
Council of Australian Governments (COAG) Health Council, 3, 87, 105
Crimson Program, 58
Criteria for the clinical use of intravenous immunoglobulin in Australia, 52–53
CSL Behring Pty Ltd, 31, 44–48, 164, 165, 166, 167
Customer Service Charter, 88
D
data developments, 55–56
Australian Haemovigilance Minimum Data Set, 56, 71
see also information communication technology
data security breach, 44
Deed of Agreement, Red Cross, 41–44
Output Based Funding Model (OBFM), 8, 28, 41
demand, 10, 22, 34, 36–40
variance between actual and NBA estimate, 23
Deputy Chief Executive, 10
diagnostic reagent products, 32, 48
Digital Transformation Agency, 60
disability reporting, 172
discards, see wastage and discards
donors and donor management, 6, 42, 43, 44
E
ecologically sustainable development, 169–171
education and training, 43, 59, 72–73
BloodSafe eLearning Australia, 13, 68, 72
staff, 96
emicizumab, 55
employees, 10, 29, 83, 90–97
enterprise agreement, 94
environmental performance, 169–171
establishment of NBA, 81
exempt contracts, 108
expenditure, see finance
extended half-life (EHL) clotting factor products,
49, 55
external scrutiny, 89
F
Factor VIIa (rFVIIa), 38–39
supply contracts, 164
Factor VIII (rFVIII), 36, 37, 55, 62
Anti-Inhibitor (FEIBA), 38, 39, 164
supply contracts, 48, 164–165
Factor IX (rFIX), 36, 38
supply contracts, 165, 166
finance, 3, 100–152, 173–174
Blood Service, 33–34, 43, 101; Output Based Funding Model (OBFM), 8, 28, 41
grant programs, 172
see also purchasing
financial assets, 103
financial statements, 110–152
audit report, 102
Flinders Medical Centre, 68
fractionation, see plasma and recombinant products
fraud control, 89
freedom of information, 172
fresh blood, 30, 33–36, 41–44, 163
donors, 6, 42, 43, 44
plasma for fractionation, 6, 34, 36, 44–46, 163
platelets, 7, 10, 35, 71, 163
see also Australian Red Cross Blood Service; patient blood management; red blood cells
frozen blood components, 43
full-time staff, 92
functions and role, 2, 14
G
gender of staff, 92–93
General Manager, see Chief Executive
governance, 80–84
blood sector data and information, 56
Board, 14–17, 87, 156–161
immunoglobulin program, 50–54
workplace health and safety, 87
grant programs, 172
Grifols Australia, 32, 46–47, 48, 167
Guidelines on the prophylactic use of Rh D immunoglobulin (Anti-D) in obstetrics, 65
H
Haematology Specialist Working Group, 54
haemophilia, see bleeding disorders
haemovigilance, 56, 71
hospital acquired anaemia, 68
human resources, 10, 29, 83, 90–97
I
Immulab Pty Ltd, 32, 48
immunoglobulins (Ig), 7, 40, 50–54, 77, 166–167
Annual Report, 56
dispense episodes, 59
governance program, 50–54
imported supplies, 7, 32, 40, 46–47, 167
RhD (Anti-D), 65
Immunology Specialist Working Group, 54
income, see finance
Indigenous staffing, 92
information communication technology (ICT),
24, 58–61
BloodNet, 6, 25, 58, 59, 60–61; Fate Module, 6, 55
BloodSTAR, 51, 52, 53, 56, 59
data security breach, 44
eLearning, 29, 96; BloodSafe, 13, 68, 72
website visitors, 7
Information Communication Technology (ICT) Committee, 58, 83
Information Framework Agreements, 56
Information Publication Scheme statement, 172
internal audit and auditors, 83–84
international engagement, 9, 17
international sector scanning, 62
inventory management, 27
Blood Service, 43
imported immunoglobulin, 47
imported plasma derived and recombinant products, 48
plasma for fractionation (CSL under CAFA and NaFAA), 46
see also BloodNet; wastage and discards
iron, 43
J
Johnson & Johnson Medical Pty Ltd, 32, 48
judicial decisions, 89
Jurisdictional Blood Committee (JBC), 28, 43, 55, 57, 66, 68
K
Keegan, Dr Anastazia, 71
key performance indicators, see performance indicators/criteria
L
legal decisions, 89
legislation, 3, 14, 80, 81, 100, 101
Public Governance, Performance and Accountability Act 2013, 21, 100, 101, 109
Public Governance, Performance and Accountability Rule 2014 (PGPA Rule), 21, 89
liabilities, see assets
M
management and accountability, 80–97
see also finance; patient blood management
market research and advertising, 169
Medical Services Advisory Committee, 43, 49, 55
Ministers, 3
MyABDR portal, 60
N
National Blood Account, 100, 101
National Blood Agreement, 3, 62, 75, 80, 81
approval under Schedule 3, 87
evaluations undertaken under Schedule 4, 55
revenue returned to Governments, 105
National Blood and Blood Product Wastage Reduction Strategy, 55, 66
National Blood Authority Act 2003, 3, 14, 80, 81, 100, 101
National Blood Product Management Implementation Strategy, 66
National Blood Product Management Improvement Strategy, 66
National Blood Sector Data and Information Governance Framework, 56
National Blood Sector Research and Development Pilot, 75–77
National Blood Supply Contingency Plan, 57
National Fractionation Agreement for Australia, 44–46
National Haemovigilance Report, 56
National Ig Interest Group, 54
National Immunoglobulin Governance Advisory Committee (NIGAC), 53, 54
National Inventory Management Framework (NIMF), 27
National Managed Fund (Blood and Blood Products) Special Account, 100, 101
National Patient Blood Management Implementation Strategy, 67, 68, 69
National Policy: Access to Government Funded Immunoglobulin Products in Australia, 51, 59
National Product List, 36
National Safety and Quality Health Service Standards, 69, 73
National Supply List, 55
National Supply Plan and Budget, 30–40, 68, 87
Neurology Specialist Working Group, 54
New South Wales Ministry of Health, 51
non-English speaking backgrounds, employees from, 92
non-financial assets, 103
non-ongoing staff, 93
Novo Nordisk Pharmaceuticals Pty Ltd, 32, 47–48, 164, 166
O
objectives, 22–77
obstetrics, 43, 65, 77
occupational health and safety, 29, 87, 96–97
Ombudsman, 89
ongoing staff, 93
online services, see information communication technology
operating result, 102–103
Blood Service, 34, 43
organisation and structure, 2–17, 80–84
organisation charts, 4, 80, 82, 86
Ortho-Clinical Diagnostics, 32, 48
Output Based Funding Model (OBFM), 8, 28, 41
overseas delegations, 9, 17
overseas sector scanning, 62
P
Parliamentary committees, 89
part-time staff, 92
patient blood management, 64–77
BloodSTAR, 51, 52, 53, 56
performance criteria and results, 25–27
Patient Blood Management (PBM) Guidelines, 66, 67, 72
people management, 10, 29, 83, 90–97
performance indicators/criteria, 22–29
Australian Red Cross Blood Service, 41, 43
business plan objectives, 87
environmental performance, 170–171
immunoglobulin governance, 51
imported immunoglobulin, 47
imported plasma derived and recombinant products, 48
plasma for fractionation (CSL under CAFA and NaFAA), 46
wastage, 24
performance pay, 96
performance reporting statement, 20–77
Perth Processing Centre, 63
Pfizer Australia Pty Ltd, 32, 47–48, 165
planning framework, 85–87
contingencies, 57
plasma and recombinant products, 30–32, 36–40, 49
supply contracts, 47–48, 164–167
supply risk mitigation, 57
see also immunoglobulins
plasma for fractionation, 6, 34, 36, 44–46, 163
plasmapheresis, see apheresis plasma
platelets, 7, 10, 35, 71, 163
policy and policy advice, 28
Portfolio Budget Statements, 21
prices, 34, 36–37, 163–167
procurement, see purchasing
productivity gains, 96
Project Governance Boards, 83
promotion and communication, 70–71
see also information communication technology
Public Governance, Performance and Accountability Act 2013, 21, 100, 101, 109
Public Governance, Performance and Accountability Rule 2014 (PGPA Rule), 21, 89
Public Service Act 1999, 3
purchasing, 108–109, 168–169
purchasing of blood and blood product supply, 3, 30–49, 163–167
contract management, 41–49
savings, 10, 34, 36–37, 45
see also inventory management
Q
Queensland Health, 43, 58
R
Rasko. Professor John, 15
recombinant products, see plasma and recombinant products
red blood cells, 7, 34–35, 71, 163
demand, 10, 34, 36
diagnostic reagent products, 32, 48
supply change management, 43
wastage and discards, 23, 27, 55
remuneration of staff, 94–95, 96
research and development, 75–77
Blood Service, 44
resource statements, 173–174
revenue, see finance
Rh D immunoglobulin, 65
risk management, 57
Royal Australian and New Zealand College of Obstetricians and Gynaecologists, 65
S
safe and efficient use, see patient blood management
salary and remuneration, 94–95, 96
satisfaction with Blood Service, 43
savings, 10, 34, 36–37, 45
wastage reductions, 27
sector monitoring, 62
sector scanning, 62
security of supply, see supply
Senior Executive Management, 83, 84
Service Charter, 88
Shire Australia Pty Ltd, 31, 47–48, 49, 62, 164, 165–166
small business, procurement initiatives to support, 109, 168
special accounts, 100, 101
Specialist Working Groups, 52, 53, 54
staff, 10, 29, 83, 90–97
stakeholders, 54, 74
engagement program, 15
standards, 69, 73
Statement on National Stewardship Expectations for the Supply of Blood and Blood Products, 66
Strategic Framework for the National Haemovigilance Program, 56, 71
supply, 10–11, 30–63, 163–167
evaluation of new products, 55
National Supply Plan and Budget, 30–40, 68, 87
performance criteria, 22–25
supply chain management, see inventory management
T
Tan, Dr Joanne, 71
tenders, see purchasing
Townsville plasma donor centre, 42, 44
training, see education and training
Tran, Professor Huyen, 15
Transplantation Specialist Working Group, 54
tribunal decisions, 89
V
values, 91
W
wastage and discards, 24, 27, 55, 66
BloodNet Fate Module, 6, 55
red blood cells, 23, 27, 55
website services, see information communication technology
whole blood, 35, 36, 163
donor management, 43
work health and safety, 29, 87, 96–97
work plans, 54, 56